Trial Profile
A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2019
Price :
$35
*
At a glance
- Drugs AZD 4017 (Primary)
- Indications Ocular hypertension
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 14 Jul 2019 Trial has been completed in UK, according to European Clinical Trials Database record.
- 29 Oct 2014 New trial record